Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 200 publications
Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Report from the 34th Acute Disease Quality Initiative (ADQI) Consensus Conference.
Journal: Journal of the American Society of Nephrology : JASN
Published: July 31, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.
Journal: JCO oncology practice
Published: June 23, 2026
Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis-Reply.
Journal: JAMA oncology
Published: June 04, 2026
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 18, 2026
An agentic AI system enhances clinical detection of immunotherapy toxicities: a multi-phase validation study.
Journal: medRxiv : the preprint server for health sciences
Published: March 23, 2026
Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Report from the 34th Acute Disease Quality Initiative (ADQI) Consensus Conference.
Journal: Journal of the American Society of Nephrology : JASN
Published: March 19, 2026
Cancer Chemoimmunotherapy: Time Will Tell.
Journal: Cancer immunology research
Published: March 18, 2026
Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 16, 2026
Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Brief Report.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 16, 2026
Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors.
Journal: NPJ precision oncology
Published: March 10, 2026
DART (NCI/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 25, 2026
Last Updated: 09/26/2026